Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research - AnaSpec has developed a series of highly sensitive assay kits for the detection of the activities of enzymes involved in epigenetics such as HDAC (Histone Deacetylase), SIRT (Sirtuin) 1 & 2 or HAT (Histone Acetyltransferases)
Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2012/12/05 - AnaSpec has developed a series of highly sensitive assay kits for the detection of the activities of enzymes involved in epigenetics such as HDAC (Histone Deacetylase), SIRT (Sirtuin) 1 & 2 or HAT (Histone Acetyltransferases).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec, EGT Group is pleased to offer a wide selection of highly sensitive HDAC (HDAC, SIRT1 & SIRT2) and HAT (CAF & p300) SensoLyte® assay kits. These assays are fluorimetric, some of which are FRET (fluorescence resonance energy transfer)-based.

Histones are the chief protein components of chromatin. They act as spools around which DNA winds. Covalent modification of histone proteins through acetylation and deacetylation affects chromatin structure and regulates gene expression. Histone hyperacetylation is well correlated with increased transcription, whereas hypoacetylation correlates with transcriptional repression. Histone deacetylases (HDACs), which catalyze the removal of acetyl groups from a ε-N-acetyl lysine amino acid on a histone, act as transcriptional repressors of genes. Histone deacetylases have been grouped into three classes. Class I (HDAC 1, 2, 3, 8) and Class II (HDAC4, 5, 6, 7, and 9) are zinc-containing hydrolase’s enzymes. The third class of deacetylases consists of the members of the sirtuin family of enzymes (Sirt 1 to 7). Inhibitors of HDAC classes I and II are being studied as a treatment for cancer and neurodegenerative diseases such as Huntington’s and Alzheimer’s diseases. The Sirtuin 1 (class III) enzyme represents a target for treatment of age-related diseases and type II diabetes.

Histone acetyltransferases (HATs) enzymes regulate the acetylation of histones and nonhistone proteins. The acetylation of the ε-amino groups of lysine residues present at histone tails correlates largely with transcriptional activation, but it is also involved in DNA replication, DNA repair and protein–protein interactions.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Cecilia Po - AnaSpec.com 
510-791-9560 cecilia[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.

Visit  BizJobs.com







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today